Circular RNA circ_0008274 enhances the malignant progression of papillary thyroid carcinoma via modulating solute carrier family 7 member 11 by sponging miR-154-3p

Jingjing Ma1) and Zhenghua Kan2)

1) Department of Endocrinology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an 223300, China
2) Department of Rehabilitation Medicine, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an 223300, China

Abstract. CircRNAs have been implicated in the progression of human cancers, including papillary thyroid carcinoma (PTC). Although circ_0008274 has been demonstrated as a potential oncogenic circRNA in PTC, our understanding of its molecular determinants is limited. The levels of circ_0008274, miR-154-3p and solute carrier family 7 member 11 (SLC7A11) mRNA were determined by quantitative real-time polymerase chain reaction (qRT-PCR). SLC7A11 protein level was assessed by western blot. Cell apoptosis, migration, and adhesion capacities were examined by flow cytometry, transwell and cell adhesion assays, respectively. The targeted correlations among circ_0008274, miR-154-3p and SLC7A11 were confirmed by a dual-luciferase reporter assay. Animal studies were performed to observe the role of circ_0008274 in tumor growth in vivo. Our data showed that the high levels of circ_0008274 and SLC7A11 were associated with poor prognosis of PTC patients. The knockdown of circ_0008274 or SLC7A11 enhanced PTC cell apoptosis and repressed cell migration and adhesion in vitro. Circ_0008274 knockdown suppressed tumor growth in vivo. Mechanistically, circ_0008274 modulated SLC7A11 expression by acting as a sponge of miR-154-3p. SLC7A11 was a functional mediator of circ_0008274 in regulating PTC cell apoptosis, migration and adhesion in vitro, and miR-154-3p overexpression repressed PTC progression in vitro by targeting SLC7A11. Our findings identified that the knockdown of circ_0008274 repressed PTC malignant progression at least in part through regulating the miR-154-3p/SLC7A11 axis, providing a promising therapeutic opportunity for PTC treatment.

Key words: Papillary thyroid carcinoma (PTC), Circ_0008274, MiR-154-3p, Solute carrier family 7 member 11 (SLC7A11)

PAPILLARY THYROID CARCINOMA (PTC) is the most prevalent type of differentiated thyroid cancer, with a long-term survival rate of >95% in the past decades [1]. However, about 10 to 15% of PTC can de-differentiate and become more aggressive, leading to a poor outcome [2, 3]. Therefore, identifying new PTC biomarkers to develop more effective diagnostic basis and therapeutic methods is still very important.

Circular RNAs (circRNAs) are endogenous, non-coding biomolecules that have been implicated in distinct physiologic and pathologic states [4]. Evidence is emerging that some circRNAs control transcriptional activity via functioning as microRNA (miRNA) sponges in various cancers, including PTC [5, 6]. For instance, Wang et al. identified that circRNA itchy E3 ubiquitin protein ligase (circ-ITCH) exerted an anti-tumor function in PTC via mediating casitas B-lineage lymphoma (CBL) expression by sponging miR-22-3p [7]. Cai et al. reported that circRNA BTB domain and CNC homolog 2 (circBACH2) served as a potential promoter in PTC tumorigenesis by targeting the miR-139-5p/LIM domain only 4 (LMO4) axis [8]. Jin and colleagues showed that circ_0004458 worked as a sponge of miR-885-5p to promote PTC malignant progression via targeting RAC1 expression [9]. Moreover, previous work in the laboratory of Zhou et al. identified circ_0008274 as a potential oncogenic circRNA in PTC [10]. Nevertheless, the precise parts played by circ_0008274 in PTC malignant progression remain unknown.

As a unit of amino acid transporters, solute carrier family 7 member 11 (SLC7A11, also named xCT)
enhances cystine uptake and glutathione synthesis during cancer metabolic processes, thereby contributing to the development and progression of human cancers [11, 12]. Interestingly, a recent report demonstrated that the increased expression of SLC7A11 was closely associated with the poor prognosis of patients with PTC [13]. Furthermore, it is still unclear whether SLC7A11 is involved in the regulation of circ_0008274 in PTC malignant progression.

Growing evidence has highlighted the association between miRNAs and PTC progression [14, 15]. It was reported that miR-154-3p was down-regulated in thyroid cancer and correlated with the outcome of the disease [16]. The study also unraveled the involvement of miR-154-3p in thyroid cancer development through targeting ras homolog family member A (RHOA). However, our understanding of the precise action of miR-154-3p in PTC malignant progression is limited.

Here, we identified that circ_0008274, a remarkably overexpressed circRNA in PTC, regulated PTC malignant progression in vitro and in vivo. Furthermore, we provided a molecular explanation, at least in part, for the oncogenic role of circ_0008274 in PTC.

**Materials and Methods**

**Clinical samples and cells**

A total of 60 PTC patients who had undergone surgery at the Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University were enrolled in this study, from October 2011 to April 2013. Tissue samples included 60 tumor tissues and 60 matched normal tissues obtained from surgery. The clinicopathological features of these patients were provided in Table 1. The follow-up information was obtained by telephone interview every three months until October 2018. The Ethics Committee of the Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University approved all protocols, and all subjects gave written informed consent.

Human PTC cell lines IHH4 and TPC1, and normal thyroid Nthy-ori 3-1 cells (all from Bnbio, Beijing, China) were propagated in RPMI-1640 medium (Thermo Fisher Scientific, Paisley, UK) supplemented with 10% fetal bovine serum (FBS, EuroClone, Milan, Italy) at 37°C, 5% CO₂, 293T cells (Bnbio) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Thermo Fisher Scientific) under standard conditions.

**RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)**

Total RNA was extracted for tissues and cells using the mirVana miRNA Isolation Kit (Invitrogen, Merelbeke, Belgium) based on the protocols of manufacturers. Total RNA was reverse-transcribed to cDNA using an iScript cDNA Synthesis Kit (Bio-Rad, Glattbrugg, Switzerland) for circ_0008274 and solute carrier family 7 member 11 (SLC7A11) mRNA expression or miScript Reverse Transcription Kit (Qiagen, Manchester, UK) for miRNAs. qRT-PCR was done using SYBR-Green Master Mix (Bio-Rad) on a Bio-Rad iCycler. Primers were listed in Supplement Table 1. Data were normalized to that of internal control GAPDH or U6 with the 2⁹ΔΔCt method [17].

**Western blot**

Western blot analyses were carried out as previously reported [18]. The primary antibodies, including SLC7A11 (ab37185, 1:1,000), intercellular adhesion molecule 1 (ICAM-1, ab109361, 1:3,000), Fibronectin (ab45688, 1:4,000), Vitronectin (ab46808, 1:5,000) and GAPDH (ab9485, 1:2,500) were used based on the directions of manufacturers (Abcam, Cambridge, UK). Horseradish peroxidase-conjugated anti-rabbit IgG antibody (ab205718, 1:5,000, Abcam) was used as the secondary antibody. The protein bands were detected using the Chemiluminescence Kit (GE Healthcare, Waukesha, WI, USA).

| Variables                              | No. of cases | Circ_0008274 expression | p value |
|----------------------------------------|--------------|------------------------|---------|
|                                        |              | High | Low |              |
| Gender                                 |              |       |     |               |
| Male                                   | 26           | 14   | 12  | 0.602         |
| Female                                 | 34           | 16   | 18  |               |
| Ages                                   |              |       |     |               |
| <45                                    | 32           | 17   | 15  | 0.755         |
| ≥45                                    | 37           | 22   | 15  |               |
| Tumor size(cm)                         |              |       |     |               |
| <2                                     | 23           | 9    | 14  | 0.126         |
| ≥2                                     | 37           | 22   | 15  |               |
| TNM stage                              |              |       |     |               |
| I-II                                   | 38           | 14   | 24  | 0.019*        |
| III                                    | 22           | 15   | 7   |               |
| Lymph node metastasis                 |              |       |     |               |
| Yes                                    | 29           | 21   | 8   | 0.017*        |
| No                                     | 31           | 13   | 18  |               |
| Tumor infiltration                    |              |       |     |               |
| Yes                                    | 24           | 19   | 5   | 0.002**       |
| No                                     | 26           | 9    | 17  |               |
Cell transfection

For the silencing in vitro studies, IHH4 and TPC1 cells (1 x 10^5) were transiently transfected with 10 nM of siRNA targeting circ_0008274 (si-circ#1, si-circ#2 or si-circ#3). For circ_0008274 overexpression studies, pCD5-ciR-based circ_0008274 overexpressing plasmid (Vector) and non-target shRNA (sh-NC) were used. SLC7A11 overexpression cells were produced using 100 ng of recombinant pcDNA-based overexpressing plasmid (SLC7A11, Ribobio), and non-target pcDNA plasmid was used as the negative control. For circ_0008274 overexpression in vivo studies, pCDS-cir-based circ_0008274 overexpressing plasmid (circ_0008274, Geneseed, Guangzhou, China) or negative plasmid (vector) was transfected into cells. For circ_0008274 knockdown in vivo studies, lentiviruses encoding shRNA specific to circ_0008274 (sh-circ_0008274) and nontarget shRNA (sh-NC) were used to transduce TPC1 cells as per the recommendation of manufacturers (HanBio, Shanghai, China). Vector-transduced cells were selected with puromycin at a final concentration of 2.5 μg/mL over 72 h.

Cell apoptosis assay

Apoptosis of cells after 24 h transfection was tested by double-staining with Annexin V-coupled fluorescein isothiocyanate (FITC) and propidium iodide (PI) as recommended by the manufacturers (Invitrogen), and data were analyzed by a FACSscan flow cytometer (BD Biosciences, Oxford, UK).

Transwell migration assay

Transfected cells were plated at 5 x 10^4 per well into the top chamber with Matrigel-precoated membrane inserts (8 μm pores, Corning, Rochester, NY, USA), and the lower chambers were filled with 15% FBS medium as a chemoattractant. After 24 h culture at 37°C, the migrated cells through the membrane inserts were determined under a 100x magnification microscope after being stained with 0.1% crystal violet for 30 min before adding 10% acetic acid for 10 min. Data were read at 570 nm with a microplate reader.

Bioinformatics and dual-luciferase reporter assay

The targeted miRNAs of circ_0008274 and the molecular targets of miR-154-3p were predicted using the starBase software (http://starbase.sysu.edu.cn/). The fragment of circ_0008274 harboring the miR-154-3p-pairing sites and the full-length 3'UTR of SLC7A11 were individually cloned into the pmirGLO vector (Promega, Charbonnières, France) to construct wild-type reporter plasmids (WT-circ_0008274 and WT-SLC7A11 3'UTR). Site-directed mutations (MUT-circ_0008274 and MUT-SLC7A11 3'UTR) in the target region were produced using the QuikChange Mutagenesis kit (Stratagene, Marcy L’Etoile, France). 100 ng of pmirGLO vector or WT-SLC7A11 3'UTR was transfected into 293T cells were transfected with together with miRNAs mimics or miR-NC mimic. 100 ng of WT-circ_0008274, MUT-circ_0008274, WT-SLC7A11 3'UTR or MUT-SLC7A11 3'UTR was cotransfected into IHH4 and TPC1 cells and miR-NC mimic or miR-154-3p mimic using Lipofectamine 3000. Twenty-four h post-transfection, cells were harvested for the luciferase activity assays based on the manufacturing guidance (Dual-luciferase Assay System, Promega).

Animal studies

All animal studies were done under the guidelines approved by the Animal Research Ethics Committee at The Affiliated Huain No. 1 People’s Research Hospital of Nanjing Medical University. About 1 x 10^7 sh-circ_0008274-transduced or sh-NC-infected TPC1 cells were subcutaneously implanted into the male BALB/c nude mice aged 6 weeks (Henan Laboratory Animal Center, Zhengzhou, China, n = 5 per group). The tumor growth was monitored every 4 days by measuring tumor size and calculating tumor volume by the formula: (length x width^2) / 0.5. Twenty-eight days later, all mice were euthanized and tumor tissues were harvested.

Statistical analysis

Data were expressed as the mean ± standard deviation (SD). A Student’s t-test or analyses of variance (ANOVA) was used to compare the measured parameters. The correlation between circ_0008274 and SLC7A11 or E2F8 expression levels in PTC tissues was determined by the Spearman correlation analysis. For survival analysis, the Kaplan-Meier method and log-rank test were used. The association between circ_0008274 and the clinicopathologic features of PTC patients was analyzed by χ^2 test. Significance values were presented as * p < 0.05, ** p < 0.01 or *** p < 0.001.
Results

High levels of circ_0008274 and SLC7A11 were associated with poor prognosis of PTC patients

To observe the clinical significance of circ_0008274 and SLC7A11, we investigated their correlations with the prognosis of these patients. According to the median of circ_0008274 or SLC7A11 expression, these patients were divided into two groups: high expression group (n = 30) and low expression group (n = 30). The data showed that the patients in the high circ_0008274 level group had a shorter survival time than those in the low circ_0008274 level group (Fig. 1A). Moreover, the patients with high SLC7A11 level had a shorter survival time than those with low SLC7A11 expression (Fig. 1B). Additionally, a strong positive correlation between circ_0008274 and SLC7A11 mRNA expression levels in PTC tissues was discovered (Fig. 1C). Furthermore, circ_0008274 expression was closely associated with the TNM stage, lymph node metastasis and tumor infiltration of these tumors (Table 1).

Knockdown of circ_0008274 enhanced PTC cell apoptosis and suppressed cell migration and adhesion in vitro

To determine the detailed function of circ_0008274 in PTC progression, we carried out in vitro loss-of-function analyses using circ_0008274-siRNAs (si-circ#1, si-circ#2 and si-circ#3). Transient transfection of circ_0008274-siRNAs, but not the scrambled oligonucleotide sequence, significantly reduced the level of circ_0008274 in both IHH4 and TPC1 cells (Fig. 2A). The transfection of si-circ#2 caused the most significant down-regulation of circ_0008274, so we selected it for further analyses (Fig. 2A). Functional experiments showed that the knockdown of circ_0008274 significantly promoted cell apoptosis (Fig. 2B), and repressed cell migration (Fig. 2C), as well as inhibited cell adhesion (Fig. 2D). Moreover, circ_0008274 silencing led to a significant decrease in the levels of ICAM-1, Fibronectin and Vitronectin in the two cell lines (Fig. 2E), demonstrating the suppression of circ_0008274 knockdown on cell adhesion.

Knockdown of SLC7A11 enhanced PTC cell apoptosis and weakened cell migration and adhesion in vitro

To directly test the biological function of SLC7A11 in PTC progression, we reduced its level using siRNAs targeting SLC7A11 (si-SLC7A11#1/2/3) in both IHH4 and TPC1 cells. Transient introduction of si-SLC7A11 remarkably decreased SLC7A11 expression in the two PTC cell lines (Fig. 3A). Owing to the most significant reduction of si-SLC7A11#3 in SLC7A11 level (Fig. 3A), we selected it for further research. Functional analyses showed that the silencing of SLC7A11 remarkably enhanced cell apoptosis (Fig. 3B), and suppressed cell migration (Fig. 3C) and adhesion (Fig. 3D). Furthermore, SLC7A11 depletion resulted in decreased levels of ICAM-1, Fibronectin and Vitronectin in both IHH4 and TPC1 cells (Fig. 3E), supporting the repressive effect of SLC7A11 silencing on cell adhesion.

SLC7A11 was a functionally important mediator of circ_0008274 in regulating PTC cell apoptosis, migration and adhesion in vitro

Our above findings demonstrated that circ_0008274 and SLC7A11 negatively regulated PTC malignant progression in vitro. These resemblances prompted us to examine whether SLC7A11 could work as a molecular mediator of circ_0008274 in PTC progression. By contrast, circ_0008274 knockdown led to a significant decrease in the expression of SLC7A11 protein, and this effect was strongly abolished by the transfection of SLC7A11 overexpressing plasmid (Fig. 4A). Further functional experiments revealed that the restored expression...
of SLC7A11 dramatically abrogated circ_0008274 knockdown-mediated pro-apoptosis (Fig. 4B), anti-migration (Fig. 4C) and anti-adhesion (Fig. 4D and 4E).

**MiR-154-3p directly interacted with circ_0008274 and SLC7A11 3’UTR**

Using the starBase software (http://starbase.sysu.edu.cn/), the data revealed that circ_0008274 and SLC7A11 3’UTR harbored putative target sequences for miR-487a-3p, miR-656-3p, miR-154-3p, miR-660-5p and miR-140-3p (Fig. 5A). By contrast, circ_0008274 silencing led to a significant increase in the levels of miR-154-3p and miR-140-3p in TPC1 cells (Fig. 5B). To preliminarily confirm whether the five miRNAs could directly target SLC7A11, we constructed SLC7A11 3’UTR wild-type luciferase reporter (WT-SLC7A11 3’UTR) and performed dual-luciferase assays. Interestingly, the transfection of miR-656-3p or miR-154-3p mimic remarkably reduced the luciferase activity of WT-SLC7A11 3’UTR (Fig. 5C). We therefore selected
**Fig. 4** SLC7A11 was a functionally important mediator of circ_0008274 in regulating PTC cell apoptosis, migration and adhesion *in vitro*. IHH4 and TPC1 cells were transfected with si-NC, si-circ#2, si-circ#2+pcDNA or si-circ#2+SLC7A11, followed by the determination of SLC7A11 protein level by western blot (A), cell apoptosis by flow cytometry (B), cell migration by transwell assay (C), cell adhesion by the adhesion assay (D), ICAM-1, Fibronectin and Vitronectin levels by western blot (E). pcDNA: negative control plasmid, SLC7A11: SLC7A11 overexpressing plasmid. **p < 0.01 or *** p < 0.001.

**Fig. 5** MiR-154-3p directly interacted with circ_0008274 and SLC7A11 3’UTR. (A) Venn diagram showing the putative targeted miRNAs of circ_0008274 and SLC7A11 identified by starBase software. Red circle: miRNA binding to circ_0008274, purple circle: miRNA binding to SLC7A11. (B) The levels of miR-487a-3p, miR-656-3p, miR-154-3p, miR-660-5p and miR-140-3p by qRT-PCR in si-NC- or si-circ#2-transfected TPC1 cells. (C) Dual-luciferase reporter assays in 293T cells cotransfected with pmirGLO vector or WT-SLC7A11 3’UTR and miR-487a-3p, miR-656-3p, miR-154-3p, miR-660-5p, miR-140-3p or miR-NC mimic. Relative luciferase activity in IHH4 and TPC1 cells cotransfected with miR-NC mimic or miR-154-3p mimic and WT-circ_0008274 or MUT-circ_0008274 (D), WT-SLC7A11 3’UTR or MUT-SLC7A11 3’UTR (E). * p < 0.05, ** p < 0.01 or *** p < 0.001.
miR-154-3p for further investigation. When we used circ_0008274 wild-type (WT-circ_0008274) or mutant-type (MUT-circ_0008274) luciferase reporter in dual-luciferase assays, the cotransfection of WT-circ_0008274 and miR-154-3p mimic into the two PTC cell lines produced lower luciferase activity than cells cotransfected with the miR-NC control but MUT-circ_0008274 significantly abrogated the suppressive effect of miR-154-3p (Fig. 5D). Furthermore, the transfection of WT-SLC7A11 3’UTR in the presence of miR-154-3p mimic caused a significant down-regulation of luciferase activity, and this effect was dramatically abolished by the mutation of the target region (MUT-SLC7A11 3’UTR) (Fig. 5E), demonstrating the validity of the target sequences for interaction.

Circ_0008274 mediated SLC7A11 expression by sponging miR-154-3p

We then determined whether circ_0008274 could modulate miR-154-3p expression in both IHH4 and TPC1 cells. The transfection efficiency of circ_0008274 overexpressing plasmid was gauged by qRT-PCR (Fig. 6A). As expected, miR-154-3p level was significantly decreased by circ_0008274 overexpression, and it was dramatically increased as a result of circ_0008274 knockdown in the two PTC cell lines (Fig. 6B). To confirm whether miR-154-3p regulated SLC7A11 expression, we manipulated miR-154-3p level in the two PTC cell lines. The transfection efficiencies of miR-154-3p mimic and anti-miR-154-3p were gauged by qRT-PCR (Fig. 6C). By contrast, SLC7A11 protein level was notably reduced by miR-154-3p overexpression, and it was strikingly elevated by miR-154-3p depletion in both cell lines (Fig. 6D).

We next asked whether circ_0008274 regulated SLC7A11 expression by miR-154-3p. As expected, the transfection of anti-miR-154-3p prominently abolished the inhibition of SLC7A11 protein expression of circ_0008274 silencing in the two PTC cell lines (Fig. 6E). Furthermore, the enforced expression of circ_0002874 led to a significant increase in the level of SLC7A11 protein, and this effect was abrogated by miR-154-3p up-regulation (Fig. 6F).

Enforced expression of miR-154-3p promoted PTC cell apoptosis and repressed migration and adhesion by down-regulating SLC7A11 in vitro

To determine whether SLC7A11 was a functional
target of miR-154-3p in regulating PTC malignant progression in vitro, we transfected miR-154-3p mimic alone or together with SLC7A11 overexpressing plasmid into both IHH4 and TCP1 cells. By contrast, the transfection of SLC7A11 overexpressing plasmid significantly abolished the reduction of miR-154-3p overexpression on SLC7A11 level in the two PTC cell lines (Fig. 7A). Functional analyses revealed that the increased expression of miR-154-3p triggered a strong enhancement in cell apoptosis (Fig. 7B) and a striking inhibition in cell migration (Fig. 7C) and adhesion (Fig. 7D and 7E). Nevertheless, these functional regulatory effects of miR-154-3p were dramatically abrogated by the restored SLC7A11 expression in the two PTC cell lines (Fig. 7B–7E).

**Knockdown of circ_0008274 hampered tumor growth in vivo**

An important question was whether circ_0008274 could influence tumor growth in vivo. To address this, we subcutaneously implanted sh-circ_0008274-transduced or sh-NC-infected TPC1 cells into the nude mice to generate the xenograft model. By contrast, the transduction of sh-circ_0008274 remarkably restrained tumor growth in vivo (Fig. 8A and 8B). Moreover, circ_0008274 and SLC7A11 levels were significantly decreased and miR-154-3p was highly increased in the tumor tissues derived from sh-circ_0008274-transduced TPC1 cells (Fig. 8C–8E). Additionally, the silencing of circ_0008274 resulted in reduced expression of ICAM-1, Fibronectin and Vitronec in the sh-circ_0008274-transduced TPC1 tumors (Fig. 8E).

**Discussion**

Accumulating evidence is pointing towards circRNAs as essential regulators in cancer biology, opening up a novel field of cancer diagnostic and therapeutic opportunities [5]. CircRNAs have been implicated in the tumorigenesis and progression of PTC [20, 21]. Here, we sought to identify the detailed role of circ_0008274 in PTC malignant progression and the mechanistic insight of the circRNA-miRNA-mRNA network mediated by circ_0008274 in PTC.

Here, we validated that the up-regulation of circ_0008274 predicted poor prognosis of PTC patients, suggesting its role as a potential prognosis marker in PTC. Cell adhesion to the extracellular matrix (ECM) is an important step of cancer tumorigenesis and metastasis [22]. ICAM-1 is an Ig-like cell adhesion molecule, and Fibronectin and Vitronec are two major extracellular matrix proteins, which play essential roles in tumor cell adhesion to ECM [23-25]. Our results reported here demonstrated that circ_0008274 silencing suppressed PTC malignant progression in vitro and in vivo, in agreement with previous work [10]. On the contrary, Liang et al. reported the down-regulated expression of circ_0008274 in lung adenocarcinoma [26], which

---

**Fig. 7** MiR-154-3p overexpression promoted cell apoptosis and repressed migration and adhesion in vitro by down-regulating SLC7A11. IHH4 and TCP1 cells were transfected with miR-NC mimic, miR-154-3p mimic, miR-154-3p mimic+pcDNA or miR-154-3p mimic+SLC7A11. (A) Western blot for SLC7A11 protein expression in transfected cells. (B) Flow cytometry for cell apoptosis. (C) Transwell assay for cell migration. (D) Cell adhesion assay for cell adhesion capacity. (E) Western blot for ICAM-1, Fibronectin and Vitronec levels. pcDNA: negative control plasmid, SLC7A11: SLC7A11 overexpressing plasmid. **p < 0.01 or *** p < 0.001.
possibly was due to the different types of tumors and diversified tumor microenvironment.

SLC7A11 has been identified as a tumor promoter in various cancers [11, 12]. For example, Robert et al. demonstrated that SLC7A11 expression was elevated in glioma and predicted poor prognosis of these patients [27]. Ji and colleagues found that the increased expression of SLC7A11 enhanced the malignant progression of non-small cell lung cancer [28]. Moreover, SLC7A11 mRNA was found to be associated with the poor prognosis outcome of PTC patients [13]. Our data first demonstrated the oncogenic role of SLC7A11 in PTC. More interestingly, we showed the regulation of circ_0008274 in PTC progression by SLC7A11.

It is widely accepted that some circRNAs exert regulatory function by working as miRNA sponges [4]. Here, we first confirmed that circ_0008274 mediated SLC7A11 expression by sponging miR-154-3p. MiR-154-3p has been demonstrated to be involved in the pathogenesis of lung cancer, breast cancer and PTC [16, 29, 30]. Here, we first identified that SLC7A11 was a functional target of miR-154-3p in regulating PTC progression in vitro. Previous reports showed that several other miRNAs, such as miR-27a and miR-375, modulated human carcinogenesis by targeting SLC7A11 [31, 32]. The direct evidence of the novel regulatory axis in PTC progression in vivo was lacked, which was expected to be performed in further work. Future work should build on the findings by determining precisely how the novel circRNA-miRNA-mRNA regulatory network modulates PTC progression in vitro and in vivo.

In conclusion, the current report identified that the knockdown of circ_0008274 hampered PTC malignant progression by the miR-154-3p/SLC7A11 axis. Our findings highlighted a new circRNA-miRNA-mRNA network in PTC, providing a promising therapeutic opportunity for PTC treatment.

**Funding**

This study was supported by the Science and Technology Development Fund of Nanjing Medical University (NMUB2018154 to JJM).

**Disclosure of Interest**

The authors declare that they have no conflicts of interest.

**References**

1. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, et al. (2015) Thyroid cancer mortality and incidence: a global overview. Int J Cancer 136: 2187–2195.
2. Asioli S, Erickson LA, Righi A, Lloyd RV (2013) Papillary thyroid carcinoma with hobnail features: histopathologic criteria to predict aggressive behavior. Hum Pathol 44: 320–328.
3. Nath MC, Erickson LA (2018) Aggressive variants of papillary thyroid carcinoma: hobnail, tall cell, columnar,
and solid. Adv Anat Pathol 25: 172–179.
4. Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB (2019) The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet 20: 675–691.
5. Kristensen LS, Hansen TB, Veno MT, Kjems J (2018) Circular RNAs in cancer: opportunities and challenges in the field. Oncogene 37: 555–565.
6. Ren H, Liu Z, Liu S, Zhou X, Wang H, et al. (2018) Profile and clinical implication of circular RNAs in human papillary thyroid carcinoma. PeerJ 6: e5363.
7. Wang M, Chen B, Ru Z, Cong L (2018) CircRNA circITCH suppresses papillary thyroid cancer progression through miR-22-3p/CBL/β-catenin pathway. Biochem Biophys Res Commun 504: 283–288.
8. Cai X, Zhao Z, Dong J, Lv Q, Yun B, et al. (2019) Circular RNA circBACH2 plays a role in papillary thyroid carcinoma by sponging miR-139-5p and regulating LMO4 expression. Cell Death Dis 10: 184.
9. Jin X, Wang Z, Pang W, Zhou J, Liang Y, et al. (2018) Upregulated hsa_circ_0004458 contributes to progression of papillary thyroid carcinoma by inhibition of miR-885-5p and activation of RAC1. Med Sci Monit 24: 5488–5490.
10. Zhou GK, Zhang GY, Yuan ZN, Pei R, Liu DM (2018) Has_circ_0008274 promotes cell proliferation and invasion involving AMPK/mTOR signaling pathway in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci 22: 8772–8780.
11. Koppula P, Zhang Y, Zhuang L, Gan B (2018) Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond) 38: 12.
12. Koppula P, Zhang Y, Zhuang L, Gan B (2017) The glutamate/cystine antiporter SLC7A11/xCT expresses in cancer cell dependency on glucose by exporting glutamate. J Biol Chem 292: 14240–14249.
13. Shen L, Qian C, Cao H, Wang Z, Luo T, et al. (2018) Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma. World J Surg Oncol 16: 235.
14. Chrusciak A, Lam AK (2015) Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: a crucial review. Exp Mol Pathol 99: 393–398.
15. Zhu G, Xie L, Miller D (2017) Expression of microRNAs in thyroid carcinoma. Methods Mol Biol 1617: 261–280.
16. Fan XD, Luo Y, Wang J, An N (2020) miR-154-3p and miR-487-3p synergistically modulate RHOA signaling in the carcinogenesis of thyroid cancer. Biosci Rep 40: BSR20193158.
17. Rivetti di Val Cervo P, Lena AM, Nicoloso M, Rossi S, Mancini M, et al. (2012) p63-microRNA feedback in keratinocyte senescence. Proc Natl Acad Sci U S A 109: 1133–1138.
18. Ding C, Yi X, Wu X, Bu X, Wang D, et al. (2020) Exosome-mediated transfer of circRNA CircNFI X enhances temozolomide resistance in glioma. Cancer Lett 479: 1–12.
19. Brown TC, Nicolson NG, Cheng J, Korah R, Carling T (2018) Characterization of cell membrane extensions and studying their roles in cancer cell adhesion dynamics. J Vis Exp 26: 56560.
20. Peng N, Shi L, Zhang Q, Hu Y, Wang N, et al. (2017) Microarray profiling of circular RNAs in human papillary thyroid carcinoma. PLoS One 12: e0170287.
21. Lan X, Xu J, Chen C, Zheng C, Wang J, et al. (2018) The landscape of circular RNA expression profiles in papillary thyroid carcinoma based on RNA sequencing. Cell Physiol Biochem 47: 1122–1132.
22. Zigler M, Dobroff AS, Bar-Eli M (2010) Cell adhesion: implication in tumor progression. Minerva Med 101: 149–162.
23. van de Stolpe A, van der Saag PT (1996) Intercellular adhesion molecule-1. J Mol Med (Berl) 74: 13–33.
24. Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, et al. (2012) Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma. Ann Surg Oncol 19: 973–980.
25. Oria VO, Lopatta P, Schmitz T, Preca BT, Nyström A, et al. (2019) ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma. Mol Oncol 13: 456–479.
26. Liang L, Zhang L (2020) Identification of circRNA-miRNA-mRNA networks for exploring the fundamental mechanism in lung adenocarcinoma. Onco Targets Ther 13: 2945–2955.
27. Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, et al. (2015) SLC7A11 axis regulates oral squamous cell carcinoma proliferation by inhibiting cell proliferation. Cancer Commun (Lond) 37: 5007–5019.
28. Li S, Meng H, Zhou F, Zhai L, Zhang L, et al. (2018) Identification of circRNA-miR-885-5p and activation of RAC1 promotes non-small cell lung cancer progression. Cancer Lett 47: 1122–1132.
29. Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, et al. (2013) MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 8: 1156–1162.
30. Li S, Meng H, Zhou F, Zhai L, Zhang L, et al. (2013) MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. Pathol Res Pract 209: 179–183.
31. Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, et al. (2019) ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma. Mol Oncol 13: 456–479.
32. Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, et al. (2013) MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 8: 1156–1162.
33. Li S, Meng H, Zhou F, Zhai L, Zhang L, et al. (2013) MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. Pathol Res Pract 209: 179–183.
34. Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, et al. (2014) Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cysteine/glutamate exchanger SLC7A11. Clin Cancer Res 20: 1990–2000.
35. Wu Y, Sun X, Song B, Qiu X, Zhao J (2017) MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion. Cancer Med 6: 1686–1697.